Application Note

Evaluation Of Biotherapeutic Sequence Coverage Using Electron Activated Dissociation (EAD)

Source: SCIEX

By Fang Wang, Zoe Zhang, Pavel Ryumin, Takashi Baba, Bill Lloyd, Jason Causon, and Kerstin Phol

GettyImages-576919878-analytics-computer-testing-research-data

Ensuring drug safety and efficacy is essential for biotherapeutics, which drives the need for in-depth characterization during their development. The data presented here demonstrate that novel electron activated dissociation (EAD) is highly comparable to traditionally used collision induced dissociation (CID) with regards to sequence coverage in a peptide mapping workflow. CID is considered the fold standard for MS/MS experiments, offering a fast dissociation mechanism, and highly reproducible results.

However, CID has known limitations. Here, a new fragmentation type based on EAD was evaluated and compared to CID, it provides better sensitivity, reproducibility, and acquisition speeds while maintaining comparable sequence coverage and fragment ion coverage. 

VIEW THE APPLICATION NOTE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Bioprocess Online